CL2020002314A1 - Anticuerpos anti-cd73 y métodos de uso de los mismos - Google Patents

Anticuerpos anti-cd73 y métodos de uso de los mismos

Info

Publication number
CL2020002314A1
CL2020002314A1 CL2020002314A CL2020002314A CL2020002314A1 CL 2020002314 A1 CL2020002314 A1 CL 2020002314A1 CL 2020002314 A CL2020002314 A CL 2020002314A CL 2020002314 A CL2020002314 A CL 2020002314A CL 2020002314 A1 CL2020002314 A1 CL 2020002314A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
present disclosure
binding moiety
tgfß
Prior art date
Application number
CL2020002314A
Other languages
English (en)
Inventor
Nicholas Stuart Wilson
Jeremy Dale Waight
Shawn Michael Jennings
Olga Ignatovich
Emmanuel Cyrille Pascal Briend
Benjamin Maxime Morin
Oliver Schon
Spencer Campbell
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of CL2020002314A1 publication Critical patent/CL2020002314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona anticuerpos que se unen específicamente a CD73 (por ejemplo, CD73 humano) y antagonizan la función de CD73. También se proporcionan anticuerpos anti-CD73 que comprenden además un resto de unión a TGFß o un resto de unión a VEGF. La presente divulgación proporciona adicionalmente composiciones farmacéuticas que comprenden estos anticuerpos, ácidos nucleicos que codifican estos anticuerpos, vectores de expresión y células huésped para producir estos anticuerpos, y métodos para tratar a un sujeto usando estos anticuerpos.
CL2020002314A 2018-03-09 2020-09-07 Anticuerpos anti-cd73 y métodos de uso de los mismos CL2020002314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862640850P 2018-03-09 2018-03-09

Publications (1)

Publication Number Publication Date
CL2020002314A1 true CL2020002314A1 (es) 2021-03-05

Family

ID=65904555

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002314A CL2020002314A1 (es) 2018-03-09 2020-09-07 Anticuerpos anti-cd73 y métodos de uso de los mismos

Country Status (19)

Country Link
US (2) US11692042B2 (es)
EP (1) EP3762421A2 (es)
JP (2) JP7319992B2 (es)
KR (1) KR20200130403A (es)
CN (2) CN112074535B (es)
AR (1) AR114275A1 (es)
AU (2) AU2019231791B2 (es)
BR (1) BR112020017382A2 (es)
CA (1) CA3093468A1 (es)
CL (1) CL2020002314A1 (es)
CR (1) CR20200392A (es)
EA (1) EA202091710A1 (es)
IL (1) IL276731A (es)
MX (1) MX2020009394A (es)
PE (1) PE20210628A1 (es)
PH (1) PH12020551317A1 (es)
SG (1) SG11202007927WA (es)
TW (1) TWI823906B (es)
WO (1) WO2019173692A2 (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849862B2 (en) * 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
WO2019173692A2 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
US11407832B2 (en) 2018-12-03 2022-08-09 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant protein targeting PD-L1 and VEGF
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
UA130408C2 (uk) 2019-09-06 2026-02-11 Ле Лаборатуар Сервьє Антитіла до cd73
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
JP2022552748A (ja) 2019-10-31 2022-12-19 フォーティ セブン， インコーポレイテッド 抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
CA3161717A1 (en) * 2019-11-15 2021-05-20 Dana LORD Biparatopic cd73 antibodies
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
TW202135823A (zh) 2020-01-03 2021-10-01 美商英塞特公司 Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
PE20221409A1 (es) * 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
AU2021246485A1 (en) * 2020-04-01 2022-11-17 The Regents Of The University Of California Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
JP2023532234A (ja) * 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ｃｄ７３抗体とその用途
CN113817770B (zh) * 2020-08-12 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Cd73基因人源化的非人动物的构建方法及应用
KR20230050378A (ko) * 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
US20240218074A1 (en) * 2020-08-17 2024-07-04 Akeso Biopharma, Inc. Anti-cd73 antibody and use thereof
US20230366033A1 (en) * 2020-09-16 2023-11-16 Board Of Regents, The University Of Texas System Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
CA3194926A1 (en) * 2020-09-23 2022-03-31 Medimmune, Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
AU2021389989A1 (en) * 2020-11-27 2023-06-08 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta
AU2021400979A1 (en) * 2020-12-15 2023-06-29 Bicara Therapeutics Inc. Combination therapy for the treatment of cancer
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
KR20230135087A (ko) * 2021-01-29 2023-09-22 암젠 인크 항-mcl1 항체를 투여하여 암을 모니터링하기 위한 물질및 방법
US20240174763A1 (en) * 2021-02-24 2024-05-30 Novoprotein Scientific Inc. Anti-human cd73 antibody and use thereof
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022256620A1 (en) * 2021-06-03 2022-12-08 The Broad Institute, Inc. Novel targets for enhancing anti-tumor immunity
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
TWI910028B (zh) * 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
US20240239916A1 (en) * 2021-07-05 2024-07-18 Trion Research Gmbh Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
AU2022375782B2 (en) 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko) 2021-12-22 2024-08-14 길리애드 사이언시즈, 인코포레이티드 이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4476733A4 (en) * 2022-02-09 2026-04-08 Absci Corp DE NOVO ANTIBODY DESIGN UNLOCKING WITH GENERAL ARTIFICIAL INTELLIGENCE
WO2023164625A2 (en) * 2022-02-25 2023-08-31 Georgia Tech Research Corporation Modified plant virus system for delivery of nucleic acids into mammalian cells
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20240165995A (ko) 2022-03-24 2024-11-25 길리애드 사이언시즈, 인코포레이티드 Trop-2 발현 암의 치료를 위한 병용요법
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CR20240451A (es) 2022-04-21 2024-12-04 Gilead Sciences Inc Compuestos de modulación de kras g12d
KR20250026284A (ko) * 2022-06-22 2025-02-25 아케소 바이오파마, 인크. 약학 조성물 및 이의 용도
KR20250028371A (ko) 2022-07-01 2025-02-28 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
WO2024010842A1 (en) * 2022-07-07 2024-01-11 The Board Of Trustees Of The Leland Stanford Junior University Targeting cells with a combination of cxcr2 inhibition and cd47 blockade
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
WO2024217447A1 (zh) * 2023-04-17 2024-10-24 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用
CR20250446A (es) 2023-04-21 2025-12-02 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
CN121336009A (zh) * 2023-05-07 2026-01-13 生物蛋白有限公司 用于治疗衰老细胞的蛋白治疗剂
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
CN121568955A (zh) * 2023-07-25 2026-02-24 免疫生物公司 Lair-2和tnt-陷阱的组合物和方法
KR20260046403A (ko) 2023-07-26 2026-04-07 길리애드 사이언시즈, 인코포레이티드 Parp7 저해제
CN121620513A (zh) 2023-07-26 2026-03-06 吉利德科学公司 Parp7抑制剂
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025076440A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. TGFβRII EXTRACELLULAR REGION VARIANTS AND USES THEREOF
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
CN118420709B (zh) * 2024-04-29 2025-02-14 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用
WO2025233264A1 (en) 2024-05-07 2025-11-13 Innate Pharma Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
CN119431583B (zh) * 2024-12-19 2025-09-30 重庆国际免疫创新中心有限公司 靶向cd155的抗体或抗原结合片段及其应用
CN120965881A (zh) * 2025-08-19 2025-11-18 合肥综合性国家科学中心大健康研究院 抗猪b细胞表面cd27的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0118311A3 (en) 1983-03-07 1987-04-29 Sheena Margaret Johnson Monoclonal factor having 5'-nucleotidase inhibitory activity
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
DE69332026T2 (de) 1992-10-29 2002-10-31 Celtrix Pharmaceuticals, Inc. Typ ii tgf-beta-bindendes rezeptorfragment als therapeutisches mittel
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
US20060134111A1 (en) 2004-12-17 2006-06-22 Genentech, Inc. Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
US7303748B2 (en) 2005-02-02 2007-12-04 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a VEGF inhibitor
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
WO2006125140A2 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
ES2449753T3 (es) 2007-03-19 2014-03-21 National Research Council Of Canada Proteínas de fusión que comprenden dos dominios de unión tgf-beta
WO2008157367A1 (en) 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
NZ590667A (en) 2008-07-02 2013-01-25 Emergent Product Dev Seattle Tgf-b antagonist multi-target binding proteins
CA3253628A1 (en) 2010-03-05 2025-11-29 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
WO2013149094A1 (en) 2012-03-28 2013-10-03 The Board Of Regents Of The University Of Texas System TGFβ TYPE II-TYPE III RECEPTOR FUSIONS
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
CA2902830C (en) 2013-03-12 2023-09-19 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US10584158B2 (en) 2013-04-17 2020-03-10 Baylor College Of Medicine Immunosuppressive TGF-β signal converter
EP3019203A4 (en) 2013-07-09 2017-04-26 President and Fellows of Harvard College Endothelial cell genes and uses thereof
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
ES2902533T3 (es) 2013-11-21 2022-03-28 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
US10358476B2 (en) 2015-04-06 2019-07-23 Acceleron Pharma Inc. Single arm type I and type II receptor fusion proteins and uses thereof
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
EP3423494A1 (en) 2016-03-04 2019-01-09 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US20200232974A1 (en) 2016-03-30 2020-07-23 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
US10077308B2 (en) 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
RU2754058C2 (ru) 2016-12-13 2021-08-26 Астеллас Фарма Инк. Антитело к cd73 человека
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof

Also Published As

Publication number Publication date
AR114275A1 (es) 2020-08-12
US20230416397A1 (en) 2023-12-28
CR20200392A (es) 2020-11-17
IL276731A (en) 2020-09-30
US20190352418A1 (en) 2019-11-21
SG11202007927WA (en) 2020-09-29
AU2022259823A1 (en) 2022-12-01
US11692042B2 (en) 2023-07-04
MX2020009394A (es) 2021-01-15
TWI823906B (zh) 2023-12-01
CA3093468A1 (en) 2019-09-12
PE20210628A1 (es) 2021-03-23
AU2019231791B2 (en) 2022-08-11
CN112074535B (zh) 2024-10-11
CN119431579A (zh) 2025-02-14
PH12020551317A1 (en) 2021-09-01
EP3762421A2 (en) 2021-01-13
CN112074535A (zh) 2020-12-11
EA202091710A1 (ru) 2021-02-16
JP7319992B2 (ja) 2023-08-02
TW201945391A (zh) 2019-12-01
WO2019173692A2 (en) 2019-09-12
AU2019231791A1 (en) 2020-09-03
KR20200130403A (ko) 2020-11-18
JP2023129543A (ja) 2023-09-14
WO2019173692A3 (en) 2019-11-14
BR112020017382A2 (pt) 2021-01-26
JP2021515559A (ja) 2021-06-24

Similar Documents

Publication Publication Date Title
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CL2018000490A1 (es) Anticuerpos anti-pd1 y sus métodos de uso
MX2021013161A (es) Polipeptidos que contienen dominios de union de novo y usos de los mismos.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
UY40829A (es) Anticuerpos anti-phf-tau y sus usos
PE20180672A1 (es) Anticuerpos anti-ctla-4 y metodos de uso de los mismos
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
NI201800055A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos.
ECSP22014455A (es) Anticuerpos anti-cd96 y sus métodos de uso
AR105634A1 (es) Anticuerpos que se unen a il 8 y sus usos
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
MX389703B (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
CL2022000096A1 (es) Anticuerpos anti-tigit y aplicación de los mismos
EA201990927A1 (ru) Антитела против lag-3 и способы их применения
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS
EA201892804A1 (ru) Антитела против tim-3 и способы их применения